Rani Therapeutics Holdings (RANI) Interest Expenses (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Interest Expenses of $2.4 million for Q1 2026, up 157.37% year-over-year from $943000.0 in Q1 2025, and up 409.87% quarter-over-quarter from $476000.0 in Q4 2025.
Rani Therapeutics Holdings (RANI) Interest Expenses (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Interest Expenses history runs 7 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 157.37% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (down 24.39% YoY), while the FY2025 annual figure was $79.1 million, up 1470.77% from the prior year.
- Interest Expenses for Q1 2026 stood at $2.4 million, up from $476000.0 in the prior quarter.
- The five-year high for Interest Expenses was $6.7 million in Q3 2024, with the low at -$2.4 million in Q4 2024.
- The 5-year median for Interest Expenses is $1.3 million (2023), against an average of $1.9 million.
- The sharpest annual moves came in 2022 and 2024: Interest Expenses soared 72000.0% in 2022, then slumped 171.4% in 2024.
- Rani Therapeutics Holdings' Interest Expenses stood at $719000.0 in 2022, then soared by 373.16% to $3.4 million in 2023, then plunged by 171.4% to -$2.4 million in 2024, then surged by 119.6% to $476000.0 in 2025, then surged by 409.87% to $2.4 million in 2026.
- Business Quant data shows RANI's Interest Expenses at $2.4 million in Q1 2026, $476000.0 in Q4 2025, and $4.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Rani Therapeutics Holdings | 163.98 Mn | 163.98 Mn | - | 8,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.04 Mn |
| Jun 30, 2026 | 4.04 Mn |
| Mar 31, 2026 | 2.43 Mn |
| Mar 31, 2026 | 2.43 Mn |
| Dec 31, 2025 | 476,000.00 |
| Dec 31, 2025 | 476,000.00 |
| Sep 30, 2025 | 4.77 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Jun 30, 2025 | 949,000.00 |
| Jun 30, 2025 | 949,000.00 |
| Mar 31, 2025 | 943,000.00 |
| Mar 31, 2025 | 943,000.00 |
| Dec 31, 2024 | -2.43 Mn |
| Dec 31, 2024 | -2.43 Mn |
| Sep 30, 2024 | 6.66 Mn |
| Sep 30, 2024 | 6.66 Mn |
| Jun 30, 2024 | 1.38 Mn |
| Jun 30, 2024 | 1.38 Mn |
| Mar 31, 2024 | 1.29 Mn |
| Mar 31, 2024 | 1.29 Mn |